Pacira BioSciences, Inc. (PCRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $23.75. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 0 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PCRX = $12.11 (-49% from the current price, the stock appears overvalued). Analyst consensus target is PCRX = $27 (+13.7% upside).
Valuation: PCRX trades at a trailing Price-to-Earnings (P/E) of 142 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.42.
Financials: revenue is $726M, +2.9%/yr average growth. Net income is $7M, growing at -22.2%/yr. Net profit margin is 1% (thin). Gross margin is 71.5% (+1.4 pp trend).
Balance sheet: total debt is $454M against $693M equity (Debt-to-Equity (D/E) ratio 0.66, moderate). Current ratio is 4.54 (strong liquidity). Debt-to-assets is 35.9%. Total assets: $1.3B.
Analyst outlook: 15 / 36 analysts rate PCRX as buy (42%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 27/100 (Fail), Growth 30/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 66/100 (Partial), Future 40/100 (Partial), Income 30/100 (Fail).
